Abstract
Molecular imaging represents an extremely important advancement in patient care and numerous agents have been developed and are being studied. Hundreds of molecular imaging agents currently exist for use in multiple modalities such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, optical imaging, general nuclear medicine and positron emission tomography (PET). In PET, only a very small percentage of these agents are being used clinically in humans and more show promise for clinical use in the short-term future. The purpose of this paper is to present a brief overview of PET agents other than 18F-fluordeoxyglucose (FDG) that are either currently in clinical use in humans or in the authors opinion are felt to show great promise for clinical use in the near future.
Keywords: Molecular imaging, molecular imaging agents, positron emission tomography, PET, PET/CT
Current Pharmaceutical Biotechnology
Title: Clinical Molecular Imaging with PET Agents Other than 18F-FDG
Volume: 11 Issue: 6
Author(s): Lance T. Hall, Aaron F. Struck and Scott B. Perlman
Affiliation:
Keywords: Molecular imaging, molecular imaging agents, positron emission tomography, PET, PET/CT
Abstract: Molecular imaging represents an extremely important advancement in patient care and numerous agents have been developed and are being studied. Hundreds of molecular imaging agents currently exist for use in multiple modalities such as magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, optical imaging, general nuclear medicine and positron emission tomography (PET). In PET, only a very small percentage of these agents are being used clinically in humans and more show promise for clinical use in the short-term future. The purpose of this paper is to present a brief overview of PET agents other than 18F-fluordeoxyglucose (FDG) that are either currently in clinical use in humans or in the authors opinion are felt to show great promise for clinical use in the near future.
Export Options
About this article
Cite this article as:
T. Hall Lance, F. Struck Aaron and B. Perlman Scott, Clinical Molecular Imaging with PET Agents Other than 18F-FDG, Current Pharmaceutical Biotechnology 2010; 11 (6) . https://dx.doi.org/10.2174/138920110792246537
DOI https://dx.doi.org/10.2174/138920110792246537 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Efficacy and Safety of Bevacizumab in Glioblastomas
Current Medicinal Chemistry Blockade of Ser16-Hsp20 Phosphorylation Attenuates Neuroprotection Dependent Upon Bcl-2 and Bax
Current Neurovascular Research Cellular Uptake and Organ Accumulation of Amphipolar Metallocorroles with Cytoprotective and Cytotoxic Properties
Anti-Cancer Agents in Medicinal Chemistry Update Clinical Application of Diffusion Tensor Imaging
Current Medical Imaging New Perspectives in Glioblastoma: Nanoparticles-based Approaches
Current Cancer Drug Targets LGI1 Affects Survival of Neuroblastoma Cells by Inhibiting Signalling through Phosphoinositide 3-Kinase
Current Signal Transduction Therapy Nanoparticles: A Neurotoxicological Perspective
CNS & Neurological Disorders - Drug Targets Boron Nitride Nanotubes: Production, Properties, Biological Interactions and Potential Applications as Therapeutic Agents in Brain Diseases
Current Nanoscience Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design Blood Brain Barrier in Hypoxic-Ischemic Conditions
Current Neurovascular Research Neuropilin-1 (NRP-1) and Magnetic Nanoparticles, a Potential Combination for Diagnosis and Therapy of Gliomas
Current Pharmaceutical Design The Role of Integrin-Mediated Cell Adhesion in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Pharmaceutical Design Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins
Recent Patents on Anti-Cancer Drug Discovery Ubiquitin-Protein Ligases - Novel Therapeutic Targets?
Current Protein & Peptide Science Nanotechnology Based Theranostic Approaches in Alzheimer's Disease Management: Current Status and Future Perspective
Current Alzheimer Research Genomic Instability in Cancer: Molecular Mechanisms and Therapeutic Potentials
Current Pharmaceutical Design